Predict your next investment

Venture Capital
hlcp.com

See what CB Insights has to offer

Investments

33

Portfolio Exits

4

Funds

1

About Harbor Light Capital Partners

Harbor Light Capital Partners is a private investment firm investing in early and growth stage companies in the technology, healthcare, energy and manufacturing sectors. It makes equity investments in the $1M to $5M range.

Harbor Light Capital Partners Headquarter Location

38 Central Square

Keene, New Hampshire, 03431,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Harbor Light Capital Partners News

Alcyone Lifesciences nabs $4 mln

Jan 16, 2014

Alcyone Lifesciences nabs $4 mln January 16, 2014 Alcyone Lifesciences has raised $4 million in Series B financing. Edgar D. Jannotta, Jr. led the round with participation from Harbor Light Capital Partners. Based in Concord, Mass., Alcyone Lifesciences develops products that treat neuropathological conditions. PRESS RELEASE CONCORD, MA–(Marketwired – Jan 15, 2014) – Alcyone Lifesciences, Inc., a privately-held medical device company developing products for the treatment of difficult neuropathological conditions, announced the closing of a Series B preferred financing of $4 million with existing and new investors. The financing was led by Edgar D. Jannotta, Jr. and included participation by Harbor Light Capital Partners, both of which were investors in the Company’s prior financings. The funds will be used to support further development of Alcyone’s platform technology for delivery of therapy to the brain as well as a novel technology to manage CSF (cerebrospinal fluid) shunt occlusions. “Having worked with the outstanding team at Alcyone Lifesciences and seen firsthand the progress made to date, I am eager to see the Company’s disruptive technologies brought into the clinic,” said Mr. Edgar Jannotta, Jr. who is also a member of the Board of Director of Alcyone Lifesciences. PJ Anand, Chief Executive Officer of Alcyone Lifesciences, commented, “This funding from our new and existing investors will allow the Company to execute on its next product development activities and clinical and regulatory milestones towards commercialization of our technologies. The additional capital resources, together with our strategic collaborations focused on the field of CNS therapy, leave us well positioned to build on the tremendous progress made in our platform therapeutic delivery technology and to continue the development of our fail-safe CSF management system. The Company is thankful to Mr. Jannotta and our current investor base for their continued support.” Nutter, McClennen & Fish LLP, led by Michelle Basil, represented the Company in the financing. Ms. Basil has represented the Company since its inception. About Alcyone LifeSciences Alcyone Lifesciences, based in Concord, Massachusetts, is a privately-held medical device company focused on development of novel treatment modalities for difficult neurological conditions. Alcyone Lifesciences was founded in 2010 by PJ Anand, CEO, Adam Fleisher, MD., Associate Professor of Neuroscience, UCSD, Banner Alzheimer’s Institute, and William Olbricht, PhD, Professor of Biomedical Engineering, Cornell University. For more information about Alcyone, please visit www.alcyonels.com. © 2015 Buyouts Insider / Argosy Group LLC

Harbor Light Capital Partners Investments

33 Investments

Harbor Light Capital Partners has made 33 investments. Their latest investment was in Alcyone Lifesciences as part of their Series E on September 9, 2020.

CBI Logo

Harbor Light Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/2/2020

Series E

Alcyone Lifesciences

$17.55M

No

1

1/17/2018

Series D

Alcyone Lifesciences

$5.14M

No

1

10/3/2017

Series B - II

Carmell Therapeutics

$1.97M

No

2

7/11/2017

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/15/2017

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/2/2020

1/17/2018

10/3/2017

7/11/2017

3/15/2017

Round

Series E

Series D

Series B - II

Series B

Series B

Company

Alcyone Lifesciences

Alcyone Lifesciences

Carmell Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$17.55M

$5.14M

$1.97M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

Harbor Light Capital Partners Portfolio Exits

4 Portfolio Exits

Harbor Light Capital Partners has 4 portfolio exits. Their latest portfolio exit was Covetrus on February 08, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/8/2019

IPO

$99M

Public

1

9/17/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2015

Acq - Talent

Subscribe to see more

$99M

Subscribe to see more

10

2/12/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/8/2019

9/17/2015

7/15/2015

2/12/2013

Exit

IPO

Acquired

Acq - Talent

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Harbor Light Capital Partners Fund History

1 Fund History

Harbor Light Capital Partners has 1 fund, including Harbor Light Capital Partners Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/3/2008

Harbor Light Capital Partners Fund

Diversified Private Equity

Closed

$30M

1

Closing Date

12/3/2008

Fund

Harbor Light Capital Partners Fund

Fund Type

Diversified Private Equity

Status

Closed

Amount

$30M

Sources

1

Harbor Light Capital Partners Team

3 Team Members

Harbor Light Capital Partners has 3 team members, including current Managing Partner, Todd Warden.

Name

Work History

Title

Status

Todd Warden

Markem-Imaje, General Catalyst, and Allaire

Managing Partner

Current

Richard A. Upton

Bear Stearns

General Partner

Current

Alan Kirshenbaum

TPG, MainStay Investments, Bear Stearns, KPMG, and CohnReznick

Founder

Former

Name

Todd Warden

Richard A. Upton

Alan Kirshenbaum

Work History

Markem-Imaje, General Catalyst, and Allaire

Bear Stearns

TPG, MainStay Investments, Bear Stearns, KPMG, and CohnReznick

Title

Managing Partner

General Partner

Founder

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.